Pipeline
Our lead candidate, AN2025 (buparlisib), will potential be the globally first approved second-line
treatment of recurrent or metastatic head and neck squamous cell carcinoma (r/m HNSCC) after disease
progression with immunotherapy, which is an area of considerable unmet need.
AN2025 (buparlisib)
oral pan-PI3K inhibitor
PIK3CA mutant solid tumors 2/3L (+Tecentriq®+AN0025)
AN0025 (palupiprant)
oral EP4 antagonist
TNBC, NSCLC, UC, MSS CRC and CC 2/3L (+Keytruda®)
Global (Excl. Japan, South Korea and partial SEA countries)
AN4005
oral PD-L1 inhibitor
Global (Excl. greater China)
AN8025
T cell/APC modulator
AN9025
oral pan-KRAS inhibitor
AN1025
oral β-catenin degrader
Abbreviations: MOA = mechanism of action; OS = overall survival; RP2D = Recommended Phase 2 Dose; LA = locally advanced; EC = esophageal cancer; RC = rectal cancer; NSCLC = non-small cell lung cancer; CRT = chemoradiation therapy; IND = Investigational New Drug; PCC = Pre-Clinical Candidate.
